Vincerx Pharma (VINC) Competitors $0.04 -0.01 (-15.14%) As of 07/3/2025 12:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VINC vs. HEPA, SRNE, REVB, BIOR, VIRX, ATXI, SYRS, NCNA, BPTSY, and VRPXShould you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Hepion Pharmaceuticals (HEPA), Sorrento Therapeutics (SRNE), Revelation Biosciences (REVB), Biora Therapeutics (BIOR), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Syros Pharmaceuticals (SYRS), NuCana (NCNA), Biophytis (BPTSY), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. Vincerx Pharma vs. Its Competitors Hepion Pharmaceuticals Sorrento Therapeutics Revelation Biosciences Biora Therapeutics Viracta Therapeutics Avenue Therapeutics Syros Pharmaceuticals NuCana Biophytis Virpax Pharmaceuticals Vincerx Pharma (NASDAQ:VINC) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Do analysts prefer VINC or HEPA? Vincerx Pharma presently has a consensus target price of $40.00, suggesting a potential upside of 104,886.88%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Vincerx Pharma is more favorable than Hepion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, VINC or HEPA? Vincerx Pharma has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Is VINC or HEPA more profitable? Vincerx Pharma's return on equity of -248.33% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vincerx PharmaN/A -248.33% -132.73% Hepion Pharmaceuticals N/A -812.56%-207.31% Do insiders & institutionals hold more shares of VINC or HEPA? 44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer VINC or HEPA? In the previous week, Vincerx Pharma and Vincerx Pharma both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 0.40 beat Vincerx Pharma's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vincerx Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hepion Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, VINC or HEPA? Vincerx Pharma is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVincerx PharmaN/AN/A-$40.16M-$20.600.00Hepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 SummaryVincerx Pharma beats Hepion Pharmaceuticals on 11 of the 12 factors compared between the two stocks. Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VINC vs. The Competition Export to ExcelMetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$199K$790.73M$5.54B$9.05BDividend YieldN/A4.84%5.24%4.02%P/E Ratio0.001.3527.4320.23Price / SalesN/A226.97422.11118.64Price / CashN/A23.4436.8958.07Price / Book0.006.298.045.67Net Income-$40.16M-$27.73M$3.18B$249.13M7 Day PerformanceN/A1.82%2.89%3.28%1 Month PerformanceN/A9.90%3.70%5.56%1 Year PerformanceN/A10.79%36.15%21.12% Vincerx Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VINCVincerx Pharma2.6439 of 5 stars$0.04-15.1%$40.00+104,886.9%-99.7%$199KN/A0.0060Gap UpHEPAHepion Pharmaceuticals0.7041 of 5 stars$0.08+14.0%N/A-99.9%$874KN/A-0.0220SRNESorrento Therapeutics0.7136 of 5 stars$0.00-36.4%N/A-81.7%$772K$60.32M0.00800News CoverageGap DownREVBRevelation Biosciences0.4772 of 5 stars$0.75-1.2%N/A-97.3%$730KN/A-0.0110Gap DownBIORBiora TherapeuticsN/A$0.15+6.5%$23.00+15,664.2%-97.7%$660K$892K-0.01120Gap UpVIRXViracta Therapeutics2.1605 of 5 stars$0.02-6.7%$1.75+10,442.2%-96.6%$660KN/A-0.0220Gap DownATXIAvenue Therapeutics2.587 of 5 stars$0.20-16.5%N/A-90.0%$639KN/A0.014Trending NewsGap DownSYRSSyros Pharmaceuticals4.3589 of 5 stars$0.02-25.8%$3.33+14,915.0%-99.5%$596K$386K-0.01120Gap DownNCNANuCana2.5391 of 5 stars$0.06-33.2%$25.00+43,454.0%-98.0%$520KN/A-0.0130Gap DownHigh Trading VolumeBPTSYBiophytisN/A$1.38flatN/A-79.7%$484KN/A0.0030VRPXVirpax Pharmaceuticals1.3788 of 5 stars$0.32+0.3%$75.00+23,634.2%-97.1%$392KN/A0.007 Related Companies and Tools Related Companies HEPA Competitors SRNE Competitors REVB Competitors BIOR Competitors VIRX Competitors ATXI Competitors SYRS Competitors NCNA Competitors BPTSY Competitors VRPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VINC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
